These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7957526)

  • 1. Food-induced increase in bioavailability of 5-methoxypsoralen.
    Ehrsson H; Wallin I; Ros AM; Eksborg S; Berg M
    Eur J Clin Pharmacol; 1994; 46(4):375-7. PubMed ID: 7957526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new micronized 5-methoxypsoralen preparation. Higher bioavailability and lower UVA dose requirement.
    Treffel P; Makki S; Humbert P; Khaldoun H; Agache P
    Acta Derm Venereol; 1992; 72(1):65-7. PubMed ID: 1350152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
    Berg M; Ros AM
    Photodermatol Photoimmunol Photomed; 1994 Oct; 10(5):217-20. PubMed ID: 7880762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of retinoids on the bioavailability of methoxy-8-psoralen].
    Beani JC; Bonnot D; Berthod F; Boitard M; Reymond JL; Beriel H; Amblard P
    Ann Dermatol Venereol; 1991; 118(4):273-5. PubMed ID: 2069337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of food on 8-methoxypsoralen serum concentration and minimal phototoxic dose.
    Bech-Thomsen N; Angelo HR; Knudsen EA
    Br J Dermatol; 1992 Dec; 127(6):620-4. PubMed ID: 1476921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of bioavailability and phototoxicity of two oral preparations of 5-methoxypsoralen.
    Stolk LM; Siddiqui AH; Westerhof W; Cormane RH
    Br J Dermatol; 1985 Apr; 112(4):469-73. PubMed ID: 3994922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism of the anti-psoriatic agent 5-methoxypsoralen in humans: comparison with rat and dog.
    John BA; Chasseaud LF; Wood SG; Forlot P
    Xenobiotica; 1992 Nov; 22(11):1339-51. PubMed ID: 1492426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [5-Methoxypsoralen: bioavailability and pharmacokinetics].
    Nitsche V; Mascher H
    Arzneimittelforschung; 1982; 32(10):1338-41. PubMed ID: 6891237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skin concentration of 8-methoxypsoralen, 5-methoxypsoralen and 4,5,8-trimethylpsoralen in guinea pigs.
    Park YK; Hann SK; Im S; Kim S
    J Dermatol Sci; 1993 Feb; 5(1):19-24. PubMed ID: 8485109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen.
    Studer-Sachsenberg EM; Piletta PA; Fathi M; Saurat JH; Salomon D
    Dermatology; 1997; 195(1):81-3. PubMed ID: 9267751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum free 5-methoxypsoralen fraction in health and psoriasis: relationship with human serum albumin concentration.
    Muret P; Humbert P; Makki S; Bechtel P; Urien S; Tillement JP
    Arch Dermatol Res; 1993; 285(5):287-90. PubMed ID: 8379689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects.
    George SA; Ferguson J
    Photodermatol Photoimmunol Photomed; 1992 Feb; 9(1):33-5. PubMed ID: 1390121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectrofluorimetric determination of 5-methoxypsoralen pharmacokinetic in patients' serum.
    Saïd A; Makki S; Muret P; Toubin G; Humbert P; Millet J
    Exp Dermatol; 1997 Apr; 6(2):57-63. PubMed ID: 9209885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peak blistering point: influence on fluid levels of 5-MOP in human skin in vivo after systemic administration.
    Humbert P; Treffel P; Makki S; Millet J; Agache P
    Arch Dermatol Res; 1991; 283(5):297-9. PubMed ID: 1929553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Methoxypsoralen inhibits 6-hydroxylation of melatonin in the rat.
    Mauviard F; Raynaud F; Geoffriau M; Claustrat B; Pévet P
    Biol Signals; 1995; 4(1):32-41. PubMed ID: 7550582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
    Stampfuss J; Kubitza D; Becka M; Mueck W
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of 8-methoxypsoralen and 5-methoxypsoralen distribution in guinea pig serum, epidermis and ocular lens.
    Wamer W; Giles A; Kornhauser A
    Photodermatol; 1987 Oct; 4(5):236-9. PubMed ID: 3697346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation.
    Tanew A; Ortel B; Rappersberger K; Hönigsmann H
    J Am Acad Dermatol; 1988 Feb; 18(2 Pt 1):333-8. PubMed ID: 3279089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of 5-methoxypsoralen in human serum.
    Wang LH; Tso M
    J Pharm Biomed Anal; 2002 Oct; 30(3):593-600. PubMed ID: 12367684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.